Epstein-Barr virus-associated lymphoproliferative disorder
MONDO:0017343A range of lymphoproliferative diseases characterized by uncontrolled proliferation of B cells, T cells, or NK cells infected with Epstein-Barr virus. Depending on host immunity and viral factors, viral persistence in host cells can induce lymphoproliferation with a diverse clinical spectrum ranging from simple reactive hyperplasia to aggressive lymphoma/leukemia with unique clinical and pathological presentations.
Also known as: EBV-associated lymphoproliferative disorder, Epstein-Barr virus-associated malignant lymphoproliferative disorder
2141 clinical trials for this condition and its sub-types, 22 tagged with Epstein-Barr virus-associated lymphoproliferative disorder itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Epstein-Barr virus-associated lymphoproliferative disorder
-
Hodgkins lymphoma 262 trials · 326 incl. sub-types
5 sub-types
- Classic Hodgkin lymphoma 147 trials · 149 incl. sub-types Sub-types →
- Nodular lymphocyte predominant Hodgkin lymphoma 5 trials · 6 incl. sub-types Sub-types →
- Lymphoma, Hodgkin, X-linked pseudoautosomal 0 trials
- Lymphoma, Hodgkin, Y-linked pseudoautosomal 0 trials
- Splenic hodgkin lymphoma 0 trials
-
Burkitt lymphoma 221 trials
2 sub-types
- Colon Burkitt lymphoma 0 trials
- Small intestinal Burkitt lymphoma 0 trials
-
Primary central nervous system lymphoma 92 trials · 103 incl. sub-types
3 sub-types
- Central nervous system non-hodgkin lymphoma 1 trial · 22 incl. sub-types Sub-types →
- Cerebral lymphoma 2 trials
- Spinal cord lymphoma 0 trials
-
Extranodal nasal NK/T cell lymphoma 51 trials
-
Plasmablastic lymphoma 20 trials
-
Primary effusion lymphoma 18 trials
-
Lymphomatoid granulomatosis 3 trials · 7 incl. sub-types
3 sub-types
- Grade III lymphomatoid granulomatosis 4 trials
- Grade I lymphomatoid granulomatosis 0 trials
- Grade II lymphomatoid granulomatosis 0 trials
-
Hydroa vacciniforme-like lymphoma 3 trials
Most studied deeper sub-types
-
New vaccine targets Hard-to-Treat EBV cancers
Disease control Not yet recruitingThis early-stage trial tests a new vaccine called KSD-101 in 55 people with relapsed or refractory EBV-associated blood cancers. The vaccine is designed to train the immune system to attack cancer cells infected with the Epstein-Barr virus. The main goals are to check safety and …
Phase 1 • Sponsor: Kousai Bio Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
New vaccine aims to fight Hard-to-Treat EBV cancers
Disease control Not yet recruitingThis study tests a vaccine called KSD-101 in 80 people with blood cancers linked to the Epstein-Barr virus (EBV). The vaccine uses a patient's own immune cells to target EBV and cancer. Researchers want to see if it can shrink tumors or keep the disease from coming back.
Sponsor: Ruijin Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
New mRNA vaccine trial targets Virus-Linked cancers
Disease control Not yet recruitingThis early-phase trial tests an mRNA immunotherapy for people with tumors linked to the Epstein-Barr virus, such as nasopharyngeal cancer, gastric cancer, and lymphoma. The treatment aims to help the immune system recognize and attack cancer cells. Researchers will check safety a…
Early phase 1 • Sponsor: Xinqiao Hospital of Chongqing • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC